Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656517 | 1.00 | EGLN1 (0.53) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29779107 | 0.88 | IDO1 (0.48) | EGLN1YTHDC1 | |
| SCHEMBL24617232 | 0.88 | IDO1 (0.48) | EGLN1YTHDC1 | |
| SCHEMBL29136034 | 0.87 | EGLN1 (0.50) | EGLN1YTHDC1 | |
| SCHEMBL29136038 | 0.84 | YTHDC1 (0.45) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29778946 | 0.84 | YTHDC1 (0.45) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29135950 | 0.81 | EGLN1 (0.44) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24617450 | 0.81 | EGLN1 (0.44) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24617353 | 0.81 | EGLN1 (0.44) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29778376 | 0.81 | EGLN1 (0.44) | EGLN1YTHDC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | disclosed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | ROCK2, ROCK1, MYLK3 | EGLN1 3652/4885YTHDC1 2530/4885KDM4E 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.